RSU 1069, a nitroimidazole containing an aziridine group

This publication has 18 references indexed in Scilit:

• Hypoxia-mediated nitro-heterocyclic drugs in the radio- and chemotherapy of cancer
  Biochemical Pharmacology, 1986
• Induction of DNA strand breaks by RSU-1069, a nitroimidazole-aziridine radiosensitizer
  Biochemical Pharmacology, 1985
• The clinical testing of Ro 03-8799—Pharmacokinetics, toxicology, tissue and tumor concentrations
  International Journal of Radiation Oncology*Biology*Physics, 1984
• RSU 1069, a 2-nitroimidazole containing an alkylating group: High efficiency as a radio- and chemosensitizer in vitro and in vivo
  International Journal of Radiation Oncology*Biology*Physics, 1984
• Radiation sensitization and chemopotentiation: Rsu 1069, a compound more efficient than misonidazole in vitro and in vivo
  British Journal of Cancer, 1984
• Non-protein thiols and cellular response to drugs and radiation
  International Journal of Radiation Oncology*Biology*Physics, 1982
• SR-2508: A 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use
  International Journal of Radiation Oncology*Biology*Physics, 1981
• Clinical testing of the radiosensitizer Ro 07-0582: Experience with multiple doses
  British Journal of Cancer, 1977
• Increased sensitivity of mammalian cell cultures to radiomimetic alkylating agents following incorporation of 5-bromodeoxyuridine into cellular DNA
  Biochemical Pharmacology, 1966
• GENETICS OF HUMAN CELL LINES
  The Journal of Experimental Medicine, 1960